↓ Skip to main content

Theranostics, Gallium-68, and Other Radionuclides

Overview of attention for book
Cover of 'Theranostics, Gallium-68, and Other Radionuclides'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 68 Ge/ 68 Ga Generators: Past, Present, and Future
  3. Altmetric Badge
    Chapter 2 Overview and Perspectives on Automation Strategies in 68 Ga Radiopharmaceutical Preparations
  4. Altmetric Badge
    Chapter 3 Post-Processing via Cation Exchange Cartridges: Versatile Options
  5. Altmetric Badge
    Chapter 4 68 Ga Generator Integrated System: Elution–Purification–Concentration Integration
  6. Altmetric Badge
    Chapter 5 Purification and Labeling Strategies for 68 Ga from 68 Ge/ 68 Ga Generator Eluate
  7. Altmetric Badge
    Chapter 6 67 Ga and 68 Ga Purification Studies: Preliminary Results
  8. Altmetric Badge
    Chapter 7 The Diversity of 68 Ga-Based Imaging Agents
  9. Altmetric Badge
    Chapter 8 Nanoparticles and Phage Display Selected Peptides for Imaging and Therapy of Cancer
  10. Altmetric Badge
    Chapter 9 “Click”-Cyclized 68 Ga-Labeled Peptides for Molecular Imaging and Therapy: Synthesis and Preliminary In Vitro and In Vivo Evaluation in a Melanoma Model System
  11. Altmetric Badge
    Chapter 10 Early Experience with 68 Ga-DOTATATE Preparation
  12. Altmetric Badge
    Chapter 11 68 Ga-Radiopharmaceuticals for PET Imaging of Infection and Inflammation
  13. Altmetric Badge
    Chapter 12 68 Ga-Labeled Bombesin Analogs for Receptor-Mediated Imaging
  14. Altmetric Badge
    Chapter 13 A Novel 68 Ga-Labeled Pteroic Acid-Based PET Tracer for Tumor Imaging via the Folate Receptor
  15. Altmetric Badge
    Chapter 14 Measurement of Protein Synthesis: In Vitro Comparison of 68 Ga-DOTA-Puromycin, [ 3 H]Tyrosine, and 2-Fluoro-[ 3 H]tyrosine
  16. Altmetric Badge
    Chapter 15 Hypoxia Imaging Agents Labeled with Positron Emitters
  17. Altmetric Badge
    Chapter 16 177 Lu/ 90 Y Intermediate-Affinity Monoclonal Antibodies Targeting EGFR and HER2/c-neu: Preparation and Preclinical Evaluation
  18. Altmetric Badge
    Chapter 17 Divergent Role of 68Ga-Labeled Somatostatin Analogs in the Workup of Patients with NETs: AIIMS Experience
  19. Altmetric Badge
    Chapter 18 Differential Uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of Gastroenteropancreatic Neuroendocrine Tumors.
  20. Altmetric Badge
    Chapter 19 High Uptake of (68)Ga-DOTATOC in Spleen as Compared to Splenosis: Measurement by PET/CT.
  21. Altmetric Badge
    Chapter 20 Rare Metastases Detected by (68)Ga-Somatostatin Receptor PET/CT in Patients with Neuroendocrine Tumors.
  22. Altmetric Badge
    Chapter 21 Comparison of different positron emission tomography tracers in patients with recurrent medullary thyroid carcinoma: our experience and a review of the literature.
  23. Altmetric Badge
    Chapter 22 PET Lung Ventilation/Perfusion Imaging Using 68 Ga Aerosol (Galligas) and 68 Ga-Labeled Macroaggregated Albumin
  24. Altmetric Badge
    Chapter 23 Combined PET/MR Imaging Using 68 Ga-DOTATOC for Radiotherapy Treatment Planning in Meningioma Patients
  25. Altmetric Badge
    Chapter 24 A Rare Case of a Large Spinal Meningioma with Mediastinal Extension and Malignant Behavior Classified Histologically as Benign
  26. Altmetric Badge
    Chapter 25 Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors in Germany: First Results of a Multi-institutional Cancer Registry.
  27. Altmetric Badge
    Chapter 26 Polish Experience in Peptide Receptor Radionuclide Therapy
  28. Altmetric Badge
    Chapter 27 PRRT as Neoadjuvant Treatment in NET
  29. Altmetric Badge
    Chapter 28 Intraoperative Somatostatin Receptor Detection After Peptide Receptor Radionuclide Therapy with 177 Lu- and 90 Y-DOTATOC (Tandem PRRNT) in a Patient with a Metastatic Neuroendocrine Tumor
  30. Altmetric Badge
    Chapter 29 Personalized Image-Based Radiation Dosimetry for Routine Clinical Use in Peptide Receptor Radionuclide Therapy: Pretherapy Experience
  31. Altmetric Badge
    Chapter 30 The Bad Berka Dose Protocol: Comparative Results of Dosimetry in Peptide Receptor Radionuclide Therapy Using 177 Lu-DOTATATE, 177 Lu-DOTANOC, and 177 Lu-DOTATOC
  32. Altmetric Badge
    Chapter 31 4D SPECT/CT Acquisition for 3D Dose Calculation and Dose Planning in 177 Lu-Peptide Receptor Radionuclide Therapy: Applications for Clinical Routine
  33. Altmetric Badge
    Chapter 32 Peptide Receptor Radionuclide Therapy with 177 Lu Labeled Somatostatin Analogs DOTATATE and DOTATOC: Contrasting Renal Dosimetry in the Same Patient
  34. Altmetric Badge
    Chapter 33 Is There a Correlation Between Peptide Receptor Radionuclide Therapy-Associated Hematological Toxicity and Spleen Dose?
  35. Altmetric Badge
    Chapter 34 Old and New Peptide Receptor Targets in Cancer: Future Directions
Attention for Chapter 18: Differential Uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of Gastroenteropancreatic Neuroendocrine Tumors.
Altmetric Badge

Mentioned by

twitter
1 X user

Readers on

mendeley
38 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Differential Uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of Gastroenteropancreatic Neuroendocrine Tumors.
Chapter number 18
Book title
Theranostics, Gallium-68, and Other Radionuclides
Published in
Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer, January 2012
DOI 10.1007/978-3-642-27994-2_18
Pubmed ID
Book ISBNs
978-3-64-227993-5, 978-3-64-227994-2
Authors

Thorsten D. Poeppel, Ina Binse, Stephan Petersenn, Harald Lahner, Matthias Schott, Gerald Antoch, Wolfgang Brandau, Andreas Bockisch, Christian Boy, Poeppel, Thorsten D., Binse, Ina, Petersenn, Stephan, Lahner, Harald, Schott, Matthias, Antoch, Gerald, Brandau, Wolfgang, Bockisch, Andreas, Boy, Christian

Abstract

Abundant expression of somatostatin receptors (sst) is a characteristic of neuroendocrine tumors (NET). Thus, radiolabeled somatostatin analogs have emerged as important tools for both in vivo diagnosis and therapy of NET. The two compounds most often used in functional imaging with positron emission tomography (PET) are (68)Ga-DOTATATE and (68)Ga-DOTATOC. Both analogs share a quite similar sst binding profile. However, the in vitro affinity of (68)Ga-DOTATATE in binding the sst subtype 2 (sst2) is approximately tenfold higher than that of (68)Ga-DOTATOC. This difference may affect their efficiency in detection of NET lesions, as sst2 is the predominant receptor subtype on gastroenteropancreatic NET. We thus compared the diagnostic value of PET/CT with both radiolabeled somatostatin analogs ((68)Ga-DOTATATE and (68)Ga-DOTATOC) in the same patients with gastroenteropancreatic NET.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 38 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 21%
Student > Ph. D. Student 6 16%
Student > Bachelor 5 13%
Student > Doctoral Student 4 11%
Student > Master 4 11%
Other 6 16%
Unknown 5 13%
Readers by discipline Count As %
Medicine and Dentistry 20 53%
Chemistry 4 11%
Pharmacology, Toxicology and Pharmaceutical Science 3 8%
Psychology 2 5%
Immunology and Microbiology 1 3%
Other 2 5%
Unknown 6 16%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 August 2012.
All research outputs
#20,165,369
of 22,675,759 outputs
Outputs from Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer
#138
of 170 outputs
Outputs of similar age
#221,176
of 244,088 outputs
Outputs of similar age from Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer
#7
of 9 outputs
Altmetric has tracked 22,675,759 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 170 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 244,088 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.